Respiratory failure & ventilation
Heterogeneous treatment effects of dexamethasone 12 mg versus 6 mg in patients with COVID‐19 and severe hypoxaemia—Post hoc exploratory analyses of the COVID STEROID 2 trial
Authors' conclusion
We found no strong evidence for HTE with 12 versus 6 mg dexamethasone daily on days alive without life support or mortality at Day 90 in patients with COVID-19 and severe hypoxaemia, although these results cannot rule out HTE either.
Study context
- Population
- Patients with COVID-19 and severe hypoxaemia
- Comparison
- Dexamethasone 12 mg vs 6 mg daily
- Primary endpoint
- Heterogeneity in treatment effects on days alive without life support and mortality, by baseline age, weight, number of comorbidities, category of respiratory failure and predicted risk of mortality
- Follow-up
- Day 90
Methodological detailspost hoc, exploratory
- Post hoc
- Exploratory
Primary result
As reported in the abstract
HTE on days alive without life support and mortality (subgroups by baseline variables)
All p values (planned analyses)
>.37
All S values
<1.43
Original publication
Heterogeneous treatment effects of dexamethasone 12 mg versus 6 mg in patients with COVID‐19 and severe hypoxaemia—Post hoc exploratory analyses of the COVID STEROID 2 trial. Acta Anaesthesiol Scand. Published 8 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →